ArticleFrontiers in neuroscience2026
Goreisan-mediated suppression of chemokine and cytokine production in astrocytes under AQP4-expressing conditions.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Aquaporin-4 (AQP4), predominantly expressed in astrocytes, has been implicated in neuroinflammation through the amplification of cytokine and chemokine production. Goreisan (GRS), a traditional Japanese herbal medicine, modulates AQP4-related water homeostasis. However, its effects on AQP4-associated inflammatory processes remain unclear. This study aimed to elucidate the anti-inflammatory effects of GRS, with particular emphasis on inflammatory responses observed under AQP4-expressing conditions. Methods: Results: GRS suppressed LPS- and TNF-α-induced cytokine and chemokine mRNA expression in primary astrocytes and AQP4-expressing NIH-3T3 cells. Conclusion: These findings indicate that the effects of GRS on inflammatory gene expression and ERK activation are associated with AQP4-expressing conditions. However, the present data do not establish AQP4 as a direct or primary molecular target of GRS. Therefore, GRS may provide a potential pharmacological approach for modulating inflammatory responses observed under AQP4-expressing conditions, although further studies are required to confirm its therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.